In these particular cases, two patients initially diagnosed with leiomyosarcoma were reclassified as having dedifferentiated liposarcoma, leading to a change in their treatment approach to include investigational MDM2 or CDK4 inhibitors. This evidence concerns the gene CDK4 and leiomyosarcoma.